-
1.发明申请ALGORITHMS FOR OUTCOME PREDICTION IN PATIENTS WITH NODE-POSITIVE CHEMOTHERAPY-TREATED BREAST CANCER 审中-公开患有结直肠癌治疗乳腺癌的患者的预后预测方法公开(公告)号：US20110166838A1
公开(公告)日：2011-07-07
申请号：US12999522
申请日：2009-06-16
Applicant: Mathias Gehrmann , Ralf Kronenwett , Udo Stropp , Christian Von Törne , Karsten Weber
Inventor： Mathias Gehrmann , Ralf Kronenwett , Udo Stropp , Christian Von Törne , Karsten Weber
IPC: G06F7/60
CPC classification number: C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , G16B20/00 , G16B25/00 , G16B40/00
Abstract: The invention relates to methods for predicting an outcome of cancer in a patient suffering from cancer, said patient having been previously diagnosed as node positive and treated with cytotoxic chemotherapy, said method comprising determining in a biological sample from said patient an expression level of a plurality of genes selected from the group consisting of ACTG1, CAl2, CALM2, CCND1, CHPT1, CLEC2B, CTSB, CXCL13, DCN, DHRS2, EIF4B, ERBB2, ESR1, FBXO28, GABRP, GAPDH, H2AFZ, IGFBP3, IGHG1, IGKC, KCTD3, KIAA0101, KRT17, MLPH, MMP1, NAT1, NEK2, NR2F2, OAZ1, PCNA, PDLIM5, PGR, PPIA, PRC1, RACGAP1, RPL37A, SOX4, TOP2A, UBE2C and VEGF; ABCB1, ABCG2, ADAM15, AKR1C1, AKR1C3, AKT1, BANF1, BCL2, BIRC5, BRMS1, CASP10, CCNE2, CENPJ, CHPT1, EGFR, CTTN, ERBB3, ERBB4, FBLN1, FIP1L1, FLT1, FLT4, FNTA, GATA3, GSTP1, Herstatin, IGF1R, IGHM, KDR, KIT, CKRT5, SLC39A6, MAPK3, MAPT, MKI67, MMP7, MTA1, FRAP1, MUC1, MYC, NCOA3, NFIB, OLFM1, TP53, PCNA, PI3K, PPERLD1, RAB31, RAD54B, RAF1, SCUBE2, STAU, TINF2, TMSL8, VGLL1, TRA@, TUBA1, TUBB, TUBB2A.
Abstract translation: 本发明涉及用于预测患有癌症的患者的癌症结果的方法，所述患者先前被诊断为淋巴结阳性并用细胞毒性化疗治疗，所述方法包括在来自所述患者的生物样品中确定多个表达水平 选自ACTG1，CA2，CALM2，CCND1，CHPT1，CLEC2B，CTSB，CXCL13，DCN，DHRS2，EIF4B，ERBB2，ESR1，FBXO28，GABRP，GAPDH，H2AFZ，IGFBP3，IGHG1，IGKC，KCTD3， KIAA0101，KRT17，MLPH，MMP1，NAT1，NEK2，NR2F2，OAZ1，PCNA，PDLIM5，PGR，PPIA，PRC1，RACGAP1，RPL37A，SOX4，TOP2A，UBE2C和VEGF; ABCB1，ABCG2，ADAM15，AKR1C1，AKR1C3，AKT1，BANF1，BCL2，BIRC5，BRMS1，CASP10，CCNE2，CENPJ，CHPT1，EGFR，CTTN，ERBB3，ERBB4，FBLN1，FIP1L1，FLT1，FLT4，FNTA，GATA3，GSTP1， Herbatin，IGF1R，IGHM，KDR，KIT，CKRT5，SLC39A6，MAPK3，MAPT，MKI67，MMP7，MTA1，FRAP1，MUC1，MYC，NCOA3，NFIB，OLFM1，TP53，PCNA，PI3K，PPERLD1，RAB31，RAD54B，RAF1， SCUBE2，STAU，TINF2，TMSL8，VGLL1，TRA @，TUBA1，TUBB，TUBB2A。
-
公开(公告)号：US07668661B2
公开(公告)日：2010-02-23
申请号：US10868437
申请日：2004-06-15
Applicant: Michael Volker , Michael Becka , Werner Kroll , Andreas Knorr , Sylvia Unger , Mathias Gehrmann , Guido Hennig , Elmar-Reinhold Burchardt , Michael J. Arthur , Alastair D. Burt , Massimo Pinzani , Detlef Schuppan , Robert P. Thiel , Christoph Petry , William Rosenberg
Inventor： Michael Volker , Michael Becka , Werner Kroll , Andreas Knorr , Sylvia Unger , Mathias Gehrmann , Guido Hennig , Elmar-Reinhold Burchardt , Michael J. Arthur , Alastair D. Burt , Massimo Pinzani , Detlef Schuppan , Robert P. Thiel , Christoph Petry , William Rosenberg
IPC: G06F7/00
CPC classification number: C12Q1/6883 , G01N33/6893 , G01N2800/085 , G06F19/00 , G06F19/24 , G16H50/20 , Y02A90/26
Abstract: The invention provides diagnostic methods, kits, and systems, and related computer-readable media, which use multiple blood marker values, including serum and plasma marker values, to aid in the diagnosis of the status or progress of a liver disease in a patient.The invention also provides methods and systems, and related computer-readable media, that use blood marker values, including serum and plasma marker values: (1) to screen for active ingredients useful in the treatment of a liver disease; (2) to aid in the selection of treatment regimens for patients that are predisposed to, or suffer from, liver disease; and (3) to aid in the design of clinical programs useful in monitoring the status or progress of liver disease in one or more patients.
Abstract translation: 本发明提供了诊断方法，试剂盒和系统以及相关的计算机可读介质，其使用多个血液标记值，包括血清和血浆标记值，以帮助诊断患者的肝脏疾病的状态或进展。 本发明还提供了使用血液标记值（包括血清和血浆标记值）的方法和系统以及相关的计算机可读介质：（1）筛选可用于治疗肝脏疾病的活性成分; （2）协助选择易患或患有肝病的患者的治疗方案; （3）协助设计有用的一个或多个病人监测肝脏病状况或进展情况的临床方案。
-
公开(公告)号：US20090069196A1
公开(公告)日：2009-03-12
申请号：US12281780
申请日：2007-03-09
Applicant: Mathias Gehrmann , Christian Von Toerne
Inventor： Mathias Gehrmann , Christian Von Toerne
CPC classification number: C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/158
Abstract: Method for the prediction of the response to epirubicin/cyclophosphamide-based chemotherapy of a breast cancer in a patient, from a tumour sample of said patient, comprising steps of determining the expression level of a group of marker genes consisting of (i) a first marker gene selected from the group consisting of MLPH, SPDEF, and AKR7A3; and (ii) a pair of second marker genes selected from the group of pairs consisting of (H2BFS and UBE2S), (BGN and ZBTB16), (ZBTB16 and EMP1), (LGALS8 and UBE2S) and (OLFML2B and ZBTB16); and (iii) a third marker gene selected from the group consisting of CYBA, ACP5, a gene specifically binding to Affymetrix probe set ID 210915 x at, LCK, GSTM3; classifying said sample as belonging to one of several breast cancer response classes from the expression levels determined; predicting the response of said breast cancer in said patient to chemotherapy from previously known characteristic properties of tumours of said one of several breast cancer response classes.
Abstract translation: 用于预测来自所述患者的肿瘤样品的患者的乳腺癌对表柔比星/环磷酰胺类化疗的反应的方法，包括确定一组标记基因的表达水平的步骤，所述标记基因组由以下组成：（i）第一 标记基因，其选自MLPH，SPDEF和AKR7A3; 和（ii）选自由（H2BFS和UBE2S），（BGN和ZBTB16），（ZBTB16和EMP1），（LGALS8和UBE2S）和（OLFML2B和ZBTB16）组成的组中的一对第二标记基因; 和（iii）选自CYBA，ACP5，特异性结合Affymetrix探针组ID 210915 x at LCK，GSTM3的基因的第三标记基因; 将所述样品从所确定的表达水平分类为几种乳腺癌反应类别之一; 从所述几种乳腺癌反应类别的肿瘤的先前已知的特征性质预测所述患者中的所述乳腺癌对化学疗法的反应。
-
公开(公告)号：US20070172907A1
公开(公告)日：2007-07-26
申请号：US10868437
申请日：2004-06-15
Applicant: Michael Volker , Michael Becka , Werner Kroll , Andreas Knorr , Sylvia Unger , Mathias Gehrmann , Guido Hennig , Elmar-Reinhold Burchardt , Michael Arthur , Alastair Burt , Massimo Pinzani , Detlef Schuppan , Robert Thiel , Christoph Petry , William Rosenberg
Inventor： Michael Volker , Michael Becka , Werner Kroll , Andreas Knorr , Sylvia Unger , Mathias Gehrmann , Guido Hennig , Elmar-Reinhold Burchardt , Michael Arthur , Alastair Burt , Massimo Pinzani , Detlef Schuppan , Robert Thiel , Christoph Petry , William Rosenberg
CPC classification number: C12Q1/6883 , G01N33/6893 , G01N2800/085 , G06F19/00 , G06F19/24 , G16H50/20 , Y02A90/26
Abstract: The invention provides diagnostic methods, kits, and systems, and related computer-readable media, which use multiple blood marker values, including serum and plasma marker values, to aid in the diagnosis of the status or progress of a liver disease in a patient. The invention also provides methods and systems, and related computer-readable media, that use blood marker values, including serum and plasma marker values: (1) to screen for active ingredients useful in the treatment of a liver disease; (2) to aid in the selection of treatment regimens for patients that are predisposed to, or suffer from, liver disease; and (3) to aid in the design of clinical programs useful in monitoring the status or progress of liver disease in one or more patients.
Abstract translation: 本发明提供了诊断方法，试剂盒和系统以及相关的计算机可读介质，其使用多个血液标记值，包括血清和血浆标记值，以帮助诊断患者的肝脏疾病的状态或进展。 本发明还提供了使用血液标记值（包括血清和血浆标记值）的方法和系统以及相关的计算机可读介质：（1）筛选可用于治疗肝脏疾病的活性成分; （2）协助选择易患或患有肝病的患者的治疗方案; （3）协助设计有用的一个或多个病人监测肝脏病状况或进展情况的临床方案。
-
公开(公告)号：US07060495B2
公开(公告)日：2006-06-13
申请号：US08989896
申请日：1997-12-12
Applicant: Mathias Gehrmann , Gerhard Seemann , Klaus Bosslet , Jörg Czech
Inventor： Mathias Gehrmann , Gerhard Seemann , Klaus Bosslet , Jörg Czech
IPC: A61K39/395 , C07K16/00
CPC classification number: C12Y302/01031 , A01K2217/05 , A61K38/00 , C07K14/705 , C07K16/18 , C07K2319/00 , C07K2319/02 , C12N9/00 , C12N9/2434 , C12N15/62
Abstract: The invention relates to compounds which contain an antigen binding region which is bound to at least one enzyme which is able to metabolize a compound (prodrug) which has little or no cytotoxicity to a cytotoxic compound (drug), where the antigen binding region is composed of a single polypeptide chain. It is advantageous for covalently bonded carbohydrates to be present on the polypeptide chain.
Abstract translation: 本发明涉及含有抗原结合区的化合物，所述抗原结合区与至少一种能够代谢对细胞毒性化合物（药物）具有很小或没有细胞毒性的化合物（前药）结合的酶，其中抗原结合区域被组成 的单个多肽链。 共价键合的碳水化合物存在于多肽链上是有利的。
-
Patent Agency Ranking
6.发明申请公开(公告)号：US20110143946A1
公开(公告)日：2011-06-16
申请号：US12674782
申请日：2008-08-25
Applicant: Mathias Gehrmann , Jan Christoph Brase , Marcus Schmidt
Inventor： Mathias Gehrmann , Jan Christoph Brase , Marcus Schmidt
CPC classification number: C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/158
Abstract: The present invention relates to a method for predicting a response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining the pattern of expression level of at least one gene of the group comprising AKR1C1, MLPH, ESR1, PGR, COMP, DCN, IGKC, CCL5, FBN1 and/or UBE2C, or of genes coregulated therewith, in said sample; c) comparing the pattern of expression levels determined in (b) with one or several reference pattern (s) of expression levels; d) identifying at least one marker gene; e) determining a molecular subtype for said sample on the basis of (d); and f) predicting from said molecular subtype response of a tumor for a chemotherapeutic agent, wherein the molecular subtype is selected from the group comprising the subtypes basal, stromal-high, stromal-low, luminal A, immune system-high, immune system-low, proliferation-high and/or proliferation-low.
Abstract translation: 本发明涉及一种用于预测患有或具有针对化疗剂的复发性妇科癌的风险的患者中的肿瘤的反应的方法，所述方法包括以下步骤：a）从所述患者获得生物样品; b）确定所述样品中包含AKR1C1，MLPH，ESR1，PGR，COMP，DCN，IGKC，CCL5，FBN1和/或UBE2C或与其结合的基因的组的至少一个基因的表达水平的模式; c）比较（b）中确定的表达水平与一种或几种表达水平的参考模式的模式; d）鉴定至少一个标记基因; e）基于（d）确定所述样品的分子亚型; 以及f）从所述化学治疗剂的肿瘤的分子亚型应答预测其中所述分子亚型选自基础基质，基质高，基质低，管腔A，免疫系统高免疫系统的亚型， 低，增殖高和/或增殖低。
-
公开(公告)号：US20090130678A1
公开(公告)日：2009-05-21
申请号：US12095922
申请日：2006-11-23
Applicant: Mathias Gehrmann , Christian Von Torne
Inventor： Mathias Gehrmann , Christian Von Torne
IPC: C12Q1/68 , C12Q1/02 , G01N33/574 , C40B30/00
CPC classification number: G01N33/57415 , C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , G01N2333/91215
Abstract: The present invention relates to the field of prognosis of a proliferative disease in a patient. More specifically, the present invention relates to methods for the identification of the likely outcome of breast cancer in a breast cancer patient. The invention also relates to methods for the identification of the likely outcome of breast cancer in a patient on the basis of the ERBB2 status of the patient and expression levels of immune genes in tumour tissue of said patient.
Abstract translation: 本发明涉及患者中增殖性疾病的预后领域。 更具体地，本发明涉及用于鉴定乳腺癌患者乳腺癌的可能结果的方法。 本发明还涉及基于患者的ERBB2状态和所述患者的肿瘤组织中的免疫基因的表达水平来鉴定患者中乳腺癌的可能结果的方法。
-
公开(公告)号：US20110172928A1
公开(公告)日：2011-07-14
申请号：US12999406
申请日：2009-06-16
Applicant: Mathias Gehrmann , Udo Stropp , Karsten Weber , Christian Von Törne , Marcus Schmidt
Inventor： Mathias Gehrmann , Udo Stropp , Karsten Weber , Christian Von Törne , Marcus Schmidt
IPC: G06F19/00
CPC classification number: C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , G16B20/00 , G16B25/00 , G16B40/00
Abstract: The present invention relates to methods for prediction of an outcome of neoplastic disease or cancer. More specifically, the present invention relates to a method for the prediction of breast cancer by determining in a biological sample from said patient an expression level of a plurality of genes selected from the group consisting of ACTG1, CA12, CALM2, CCND1, CHPT1, CLEC2B, CTSB, CXCL13, DCN, DHRS2, EIF4B, ERBB2, ESR1, FBXO28, GABRP, GAPDH, H2AFZ, IGFBP3, IGHG1, IGKC, KCTD3, KIAA0101, KRT17, MLPH, MMP1, NAT1, NEK2, NR2F2, OAZ1, PCNA, PDLIM5, PGR, PPIA, PRC1, RACGAP1, RPL37A, SOX4, TOP2A, UBE2C and VEGF.
Abstract translation: 本发明涉及用于预测肿瘤性疾病或癌症的结果的方法。 更具体地，本发明涉及通过在来自所述患者的生物样品中测定多种选自ACTG1，CA12，CALM2，CCND1，CHPT1，CLEC2B的多种基因的表达水平来预测乳腺癌的方法 ，CTSB，CXCL13，DCN，DHRS2，EIF4B，ERBB2，ESR1，FBXO28，GABRP，GAPDH，H2AFZ，IGFBP3，IGHG1，IGKC，KCTD3，KIAA0101，KRT17，MLPH，MMP1，NAT1，NEK2，NR2F2，OAZ1，PCNA，PDLIM5 ，PGR，PPIA，PRC1，RACGAP1，RPL37A，SOX4，TOP2A，UBE2C和VEGF。
-
公开(公告)号：US20090311700A1
公开(公告)日：2009-12-17
申请号：US12441748
申请日：2007-09-25
Applicant: Mathias Gehrmann , Christian von Törne
Inventor： Mathias Gehrmann , Christian von Törne
CPC classification number: C12Q1/6886 , C12Q2600/112 , C12Q2600/118
Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer in untreated breast cancer patients. More specific, the present invention relates to the prognosis of breast cancer based on measurements of the expression levels of marker genes in tumor samples of breast cancer patients. Marker genes are disclosed which allow for an accurate prognosis of breast cancer in patients having node negative, fast proliferating breast cancer.
Abstract translation: 本发明涉及未经治疗的乳腺癌患者乳腺癌预后的方法，试剂盒和系统。 更具体地说，本发明是基于乳腺癌患者肿瘤样本中标记基因表达水平的测定，涉及乳腺癌的预后。 公开了标记基因，其允许在具有淋巴结阴性，快速增殖的乳腺癌的患者中对乳腺癌的准确预后。
-
公开(公告)号：US07273727B2
公开(公告)日：2007-09-25
申请号：US11135155
申请日：2005-05-23
Applicant: Mathias Gehrmann , Gerhard Seeman , Klaus Bosslet , Jorg Czech
Inventor： Mathias Gehrmann , Gerhard Seeman , Klaus Bosslet , Jorg Czech
CPC classification number: C12Y302/01031 , A01K2217/05 , A61K38/00 , C07K14/705 , C07K16/18 , C07K2319/00 , C07K2319/02 , C12N9/00 , C12N9/2434 , C12N15/62
Abstract: The invention relates to compounds which contain an antigen binding region which is bound to at least one enzyme which is able to metabolize a compound (prodrug) which has little or no cytotoxicity to a cytotoxic compound (drug), where the antigen binding region is composed of a single polypeptide chain. It is advantageous for covalently bonded carbohydrates to be present on the polypeptide chain.
Abstract translation: 本发明涉及含有抗原结合区的化合物，所述抗原结合区与至少一种能够代谢对细胞毒性化合物（药物）具有很小或没有细胞毒性的化合物（前药）结合的酶，其中抗原结合区组成 的单个多肽链。 共价键合的碳水化合物存在于多肽链上是有利的。
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.025 seconds)
